Differential localisation of the renin-angiotensin system in de-novo lesions and in-stent restenotic lesions in in-vivo human coronary arteries

Cardiovascular Research

Volumn 59, Issue 4, 2003, Pages 980-987

  Wagenaar, Lodewijk J ^a   Van Boven, Ad J ^a   Van Der Wal, Allard C ^b   Amoroso, Giovanni ^a   Tio, René A ^a   Van Der Loos, Chris M ^b   Becker, Anton E ^b   Van Gilst, Wiek H ^a,c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Coronary disease; Receptors; Renin angiotensin system; Restenosis; Stents

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; RENIN;

ADULT; ARTERY CATHETER; ARTICLE; ATHERECTOMY; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL BIOPSY; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DE NOVO LESION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; IN STENT RESTENOTIC LESION; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTENOSIS; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CHI-SQUARE DISTRIBUTION; CORONARY DISEASE; CORONARY RESTENOSIS; CORONARY VESSELS; HUMANS; MACROPHAGES; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; STENTS;

EID: 1642374049     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(03)00520-0     Document Type: Article

References (40)

1. Hoshida S., Kato J., Nishino M., et al. Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome. Circulation. 103:2001;630-633.
2. Schieffer B., Schieffer E., Hilfiker-Kleiner D., et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 101:2000;1372-1378.
3. van der Wal A.C., Becker A.E., van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterised by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 89:1994;36-44.
4. Diet F., Pratt R.E., Berry G.J., et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 94:1996;2756-2767.
5. Ohishi M., Ueda M., Rakugi H., et al. Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. J Hypertens. 15:1997;1295-1302.
6. Fukuhara M., Geary R.L., Diz D.I., et al. Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension. 35:2000;353-359.
7. Serruys P.W., Kay I.P., Disco C., Deshpande N.V., de Feyter P.J. Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the BElgian NEtherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter ultrasound stent in coronaries. J Am Coll Cardiol. 34:1999;1067-1074.
8. Hoffmann R., Mintz G.S., Dussaillant G.R., et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 94:1996;1247-1254.
9. Moreno P.R., Palacios I.F., Leon M.N., et al. Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue. Am J Cardiol. 84:1999;462-466.
10. Daemen M.J., Lombardi D.M., Bosman F.T., Schwartz S.M. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 68:1991;450-456.
11. Prescott M.F., Webb R.L., Reidy M.A. Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist. Effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am J Pathol. 139:1991;1291-1296.
12. Nakajima M., Hutchinson H.G., Fujinaga M., et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA. 92:1995;10663-10667.
13. van der Loos CM. Immunoenzyme multiple staining methods. RMS Handbook No. 45, BIOS Scientific Publishers, Oxford, UK, 1999.
14. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 342:2000;145-153.
15. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
16. Powell J.S., Clozel J.P., Muller R.K., et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 245:1989;186-188.
17. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Circulation. 86:1992;100-110.
18. Faxon D.P. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol. 25:1995;362-369.
19. Timmermans P.B., Wong P.C., Chiu A.T., et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 45:1993;205-251.
20. McConnaughey M.M., McConnaughey J.S., Ingenito A.J. Practical considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol. 39:1999;547-559.
21. Pastore L., Tessitore A., Martinotti S., et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation. 100:1999;1646-1652.
22. Hope S., Brecher P., Chobanian A.V. Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am J Hypertens. 12:1999;28-34.
23. Navalkar S., Parthasarathy S., Santanam N., Khan B.V. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol. 37:2001;440-444.
24. Komatsu R., Ueda M., Naruko T., Kojima A., Becker A.E. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation. 98:1998;224-233.
25. Farb A., Sangiorgi G., Carter A.J., et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 99:1999;44-52.
26. Virmani R., Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol. 10:1999;499-506.
27. Briand V., Riva L., Galzin A.M. Characterization of the angiotensin II AT1 receptor subtype involved in DNA synthesis in cultured vascular smooth muscle cells. Br J Pharmacol. 112:1994;1195-1201.
28. Hafizi S., Chester A.H., Allen S.P., Morgan K., Yacoub M.H. Growth response of human coronary smooth muscle cells to angiotensin II and influence of angiotensin AT1 receptor blockade. Coron Artery Dis. 9:1998;167-175.
29. Ribichini F., Pugno F., Ferrero V., et al. Angiotensin-converting enzyme tissue activity in the diffuse in-stent restenotic plaque. Circulation. 101:2000;E33-E35.
30. Okimoto T., Imazu M., Hayashi Y., et al. Quinapril with high affinity to tissue angiotensin-converting enzyme reduces restenosis after percutaneous transcatheter coronary intervention. Cardiovasc Drugs Ther. 15:2001;323-329.
31. Kondo J., Sone T., Tsuboi H., et al. Effect of quinapril on intimal hyperplasia after coronary stenting as assessed by intravascular ultrasound. Am J Cardiol. 87:2001;443-445.
32. Okumura K., Sone T., Kondo J., et al. Quinapril prevents restenosis after coronary stenting in patients with angiotensin-converting enzyme D allele. Circ J. 66:2002;311-316.
33. Ellis S.G., Lincoff A.M., Whitlow P.L., et al. Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stenting. Am J Cardiol. 89:2002;937-940.
34. Meurice T., Bauters C., Hermant X., et al. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. Lancet. 357:2001;1321-1324.
35. Amant C., Bauters C., Bodart J.C., et al. D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation. 96:1997;56-60.
36. Ribichini F., Steffenino G., Dellavalle A., et al. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme: a major risk factor and a marker of risk for coronary stent restenosis. Circulation. 97:1998;147-154.
37. Koch W., Kastrati A., Mehilli J., et al. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is not associated with restenosis after coronary stent placement. Circulation. 102:2000;197-202.
38. Agema W.R., Jukema J.W., Pimstone S.N., Kastelein J.J. Genetic aspects of restenosis after percutaneous coronary interventions; towards more tailored therapy. Eur Heart J. 22:2001;2058-2074.
39. Jorgensen E., Kelbaek H., Helqvist S., et al. Predictors of coronary in-stent restenosis: importance of angiotensin-converting enzyme gene polymorphism and treatment with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 38:2001;1434-1439.
40. Peters S., Gotting B., Trummel M., Rust H., Brattstrom A. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the Val-PREST trial. J Invasive Cardiol. 13:2001;93-97.